Media MICE

15/08/2026

“Dear younger me…buckle up.” That’s essentially Dr. Albert Khouri’s message.

From the unpredictability of early trabeculectomy days to today’s era of earlier intervention and precision glaucoma surgery, he’s watched the field evolve faster than many imagined.

Watch as Dr. Khouri reflect on the lessons that only decades in glaucoma can teach.

What would you tell your younger self?

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.

Glaukos

15/08/2026

What happens when you leave home and move halfway across the globe to pursue your dreams and passions?

Chris McBride, Media MICE’s Content Producer & Editorial Creative Lead, has lived in Da Nang, Vietnam, for 12 years. What started as a journey to see what’s out there in the world evolved into a creative career, a community hub, and a life deeply connected to the city he chose to call home.

In this video, Chris opens up about the realities of living abroad, the community he’s built over the years, the lessons learned, and the authentic parts of the journey that don’t always make the highlight reel.

Watch here: https://www.youtube.com/watch?v=XUPYLQoqF6Q

Living in Da Nang, Vietnam on $1,500 a Month — His Honest Exp...

14/08/2026

Waiting for glaucoma to progress before intervening has long been the default. Dr. Andreas Cordes thinks it doesn't have to be.

In this video, he explores why interventional glaucoma is less about a new technology and more about a new way of thinking—one that prioritizes earlier, safer intervention before visual field loss occurs, and sees MIGS as a timely and well-tolerated option for the right patient.

Watch to hear why the shift toward earlier intervention may be one of the most important conversations in glaucoma management today.

Learn more at www.glaukos.com.

©2026 Glaukos Corporation. All rights reserved. Glaukos®, iStent infinite® and TMB® are registered trademarks of Glaukos Corporation. PM-EU-0451

Participating experts were compensated by Glaukos for their time.

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public.

iStent infinite® IMPORTANT SAFETY INFORMATION: www.glaukos.com/en-uk/glaucoma/products/istent-infinite/

14/08/2026

Standalone MIGS eyes are notoriously hyperemic. Without the vasoconstrictive help of phenylephrine used during phacoemulsification, blood can easily obscure your visualization.

At ASCRS 2026, Dr. Nicole Bajic shared how the updated high-contrast green light of the iTrack™ Advance enhances tracking visibility to solve this exact visual challenge.

The iTrack™ Advance has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) for the treatment of open-angle glaucoma.

INDICATIONS (USA): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures.* The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

*The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.

The ab interno surgical technique is not an on label indication for the iTrack™ Advance in the USA.

INDICATIONS (International): The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.

Nova Eye Medical

13/08/2026

Be part of the conversations shaping the future of retinal medicine.

EURETINA 2026 returns to Vienna from 1–4 October, bringing together leading experts to share the latest advances in retinal research, surgery and patient care.

Register today and join colleagues from across the world.

🔗 https://euretina.org/vienna-2026/registration/

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.

13/08/2026

Discover every critical stage of EVO ICL™ from global experts in the EVOlive™ Webinar from STAAR Surgical™! From patient selection to surgical technique and post-op care, this four-part series covers it all.

See how the right EVO ICL candidate is identified and how the lens is sized with confidence. Watch the full clip at https://youtu.be/vulJ-KWUHFg?si=n9n0qOx52UQguo9i to hear from the experts.

Find out how post-op vault and IOP decisions define long-term EVO ICL outcomes—and when clinical judgment matters most. Watch the full clip at https://www.youtube.com/watch?v=VYjnwbqgAjc&list=PLVJ-rjc_nI5c&index=3&t=1s to learn how the panel navigates each one.

Learn which surgical factors shape EVO ICL vault outcomes—and why the first week after surgery matters just as much as the OR. Watch the full clip at https://www.youtube.com/watch?v=Q2Z71JRPLVM&list=PLVJ-rjc_nI5c&index=4&t=1s to see how each decision is made.

Top surgeons share why EVO ICL leads in patient referrals among refractive procedures— and the data behind it. Watch the full clip at https://www.youtube.com/watch?v=gIlE80BJOk8&list=PLVJ-rjc_nI5c&index=5 to see why EVO ICL stands out.
Want to learn more? Visit https://staaruniversity.com/

The EVO ICL lens is an Rx only surgical implant that corrects distance vision. Surgeons must be certified prior to use including training on contraindications, surgical procedure and potential benefits, risks, and complications of both the surgery and the lens. Click https://edfu.staar.com/edfu/ for Important Safety Information.

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.

12/08/2026

Big news from the MICE team!

Four years running, and we’re still ESCRS’s video partner of choice. Media MICE is officially back as the Preferred Vendor for Video Coverage at the 2026 Congress, taking place September 11–15 at Excel London.

We’ll be on the ground with cameras rolling, capturing high-impact video stories, sitting down with key opinion leaders for in-depth interviews, and catching all the can’t-miss moments from the biggest sessions and the exhibition floor.

Exhibiting or launching something big at ESCRS this year? We’d love to help put your brand or product in the spotlight. Reach out to discuss video coverage options before the Congress kicks off.

Mark your calendars, this is THE event for cataract and refractive surgery this year. For more on the action visit congress.escrs.org/.

The European Society of Cataract and Refractive Surgeons (ESCRS)

12/08/2026

Innovation doesn’t always shout. Sometimes it quietly solves problems surgeons face every day.

This article takes a closer look at two South Korean companies engineering solutions for very different clinical challenges through precision engineering.

RET Inc. is rethinking IOL delivery with preloaded injector systems designed for smooth, controlled implantation. With Us Vision is taking on glaucoma with sustained intraocular drug delivery powered by nanotechnology.

Different technologies. Different diseases. One shared obsession to make better eye care possible.

Read the full article: https://mediamice.com/engineering-precision-from-iol-delivery-to-sustained-glaucoma-therapy/

Learn more at retinc.kr/.

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public. Products or therapies discussed may not be registered or approved in all jurisdictions, including Singapore.

11/08/2026

Men taking Cialis long-term for urinary symptoms have a 22% higher risk of developing glaucoma. That’s this week’s Editor’s Pick in Crosslink, and it’s the kind of finding that should be on every ECP’s radar.

Here’s a glimpse into this week’s top eye care news:
- Missing anti-VEGF follow-up visits cost nAMD patients nearly 5 letters of vision
- 95.3% of ophthalmology clinic letters at Moorfields fell below recommended patient readability standards
- A third of teenagers haven’t had a comprehensive eye exam in the past year
- AI in surgical retina: how explainability is becoming key to clinician trust
- Omni Ultra receives FDA clearance
- Medicare physician payments have declined 33% in real terms since 2001. The AOA is pushing back.

All in this week’s Crosslink, your weekly digest of the top headlines in eye care.
https://mediamice.com/eye-care-news-gaps-glaucoma-and-gen-z/

Ophthalmology and optometry news and links from 8/03/26 to 8/10/26.

11/08/2026

Glaucoma patients are getting younger, and younger patients often have different priorities.

Ms Shreya Haldar is seeing more people in their 40s balancing careers, young families and busy lives, all while managing a chronic disease. In this video, she discusses why that shift is changing the way she approaches glaucoma care, with a greater emphasis on earlier intervention, reducing drop burden and thinking long term from the very first treatment decision.

Watch to hear why modern glaucoma management is about helping patients live their lives…not just lowering pressure.

Learn more at www.glaukos.com

©2026 Glaukos Corporation. All rights reserved. Glaukos®, iStent infinite® and and TMB® are registered trademarks of Glaukos Corporation. PM-EU-0450

Participating experts were compensated by Glaukos for their time.

This content is intended exclusively for healthcare professionals and eye care practitioners. It is not intended for the general public.

iStent infinite® IMPORTANT SAFETY INFORMATION: www.glaukos.com/en-uk/glaucoma/products/istent-infinite/